Daily Endocrinology Research Analysis
Top endocrinology-impacting studies span translational therapeutics and mechanistic insights. A phase 3 randomized trial shows a fixed-dose combination of obicetrapib plus ezetimibe yields robust additional LDL-C lowering. Mechanistic work links obese gut microbiota to bone fragility via senescent macrophages and grancalcin; another clinical–mechanistic study shows marine n-3 PUFAs improve sleep in type 2 diabetes by restoring circadian clock signaling.
Summary
Top endocrinology-impacting studies span translational therapeutics and mechanistic insights. A phase 3 randomized trial shows a fixed-dose combination of obicetrapib plus ezetimibe yields robust additional LDL-C lowering. Mechanistic work links obese gut microbiota to bone fragility via senescent macrophages and grancalcin; another clinical–mechanistic study shows marine n-3 PUFAs improve sleep in type 2 diabetes by restoring circadian clock signaling.
Research Themes
- Lipid-lowering therapeutics and cardiovascular risk modification
- Microbiome–immune crosstalk driving skeletal health in obesity
- Nutraceutical modulation of circadian rhythms in type 2 diabetes
Selected Articles
1. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial.
In a multicenter phase 3 RCT (n=407), a fixed-dose obicetrapib–ezetimibe combination achieved substantial LDL-C reduction versus placebo and each monotherapy over 84 days, with similar safety across arms. Results support a convenient single-pill option to intensify lipid lowering in high-risk patients.
Impact: High-quality randomized evidence in a top journal demonstrates additive LDL lowering with a novel CETP inhibitor–ezetimibe coformulation, addressing residual risk on background therapy or statin intolerance.
Clinical Implications: Consider the obicetrapib–ezetimibe fixed-dose combination to intensify LDL-C lowering in ASCVD or high-risk patients not at goal on maximally tolerated therapy or with statin intolerance, pending outcomes data.
Key Findings
- FDC lowered LDL-C by −48.6% vs placebo at day 84; −27.9% vs ezetimibe; −16.8% vs obicetrapib.
- Obicetrapib monotherapy reduced LDL-C by 31.9% vs placebo.
- Adverse events and serious adverse events were similar across treatment arms.
Methodological Strengths
- Randomized, double-blind, placebo-controlled, multi-arm design
- Prospective registration and intention-to-treat analysis
Limitations
- Short duration (84 days) without cardiovascular outcomes
- Exclusion of background ezetimibe limits generalizability to all real-world regimens
Future Directions: Longer-term trials assessing ASCVD outcomes and diverse populations, including varying statin backgrounds, are needed to define clinical benefit and positioning.
BACKGROUND: Reducing LDL cholesterol prevents atherosclerotic cardiovascular disease (ASCVD) events. The aim of this study was to evaluate the LDL cholesterol-lowering efficacy of a fixed-dose combination (FDC) of obicetrapib, a CETP inhibitor, and ezetimibe. METHODS: This randomised, double-blind trial across 48 US sites including hospitals, private and group practices, and independent research centres included participants at least 18 years old with pre-existing or high risk for ASVCD or heterozygous familial hypercholesterolaemia with LDL cholesterol concentrations of 1·8 mmol/L (70 mg/dL) or greater despite maximally tolerated lipid-lowering therapy excluding ezetimibe, or having statin intolerance. Participants were randomly assigned (1:1:1:1) to obicetrapib 10 mg plus ezetimibe 10 mg FDC, obicetrapib 10 mg monotherapy, ezetimibe 10 mg monotherapy, or placebo administered daily for 84 days. The co-primary endpoints in the intention-to-treat population were the percent LDL cholesterol changes in the FDC group compared with placebo, ezetimibe monotherapy, and obicetrapib monotherapy, and the placebo-adjusted change in the obicetrapib monotherapy group. The trial was prospectively registered (NCT06005597) and is completed. FINDINGS: Between March 4 and July 3, 2024, 407 participants were randomly assigned. The median age was 68·0 years (IQR 62·0-73·0) and 177 (43%) were female. Mean baseline LDL cholesterol was 2·4 mmol/L, 2·5 mmol/L, 2·6 mmol/L, and 2·5 mmol/L in the placebo (n=102), ezetimibe monotherapy (n=101), obicetrapib monotherapy (n=102), and FDC groups (n=102), respectively. At day 84, percent differences in LDL cholesterol reduction with the FDC were -48·6% (95% CI -58·3 to -38·9) versus placebo, -27·9% (-37·5 to -18·4) versus ezetimibe, and -16·8% (-26·4 to -7·1) versus obicetrapib. Obicetrapib monotherapy decreased LDL cholesterol by 31·9% (22·1 to 41·6) versus placebo. Adverse event rates were similar in the FDC (52 [51%] of 102), obicetrapib (55 [54%] of 102), and ezetimibe (54 [53%] of 101) groups and lowest with placebo (38 [37%] of 102). Serious adverse event rates were generally similar across FDC (three [3%] of 102), obicetrapib (six [6%] of 102), ezetimibe (seven [7%] of 101), and placebo (four [4%] of 102) groups. Deaths occurred in one [1%] of 102 participants with FDC, one [1%] of 102 with obicetrapib, one [1%] of 101 with ezetimibe, and none with placebo. INTERPRETATION: Combination therapy of obicetrapib and ezetimibe significantly reduced LDL cholesterol. This oral, single-pill therapy could improve LDL cholesterol management in patients with pre-existing or high risk for ASCVD. FUNDING: NewAmsterdam Pharma.
2. Gut Microbiota Modulates Obesity-Associated Skeletal Deterioration Through Macrophage Aging and Grancalcin Secretion.
Obese microbiota induce senescence in bone marrow macrophages, upregulating grancalcin via TLR4 activation; Gca knockout and anti-grancalcin antibody protect against bone loss in mice. Human data (n=40) show higher serum grancalcin in obesity, supporting translational relevance.
Impact: Identifies a microbiome–immune axis and a druggable effector (grancalcin) linking obesity to skeletal deterioration, with genetic and antibody-based rescue in vivo.
Clinical Implications: Grancalcin and senescent macrophages emerge as therapeutic targets to mitigate obesity-associated bone loss; serum grancalcin could be explored as a biomarker.
Key Findings
- Obese mice and obese-FMT recipients exhibited increased senescent bone marrow macrophages and elevated grancalcin.
- LPS from obese microbiota drove grancalcin expression via TLR4 in senescent macrophages.
- Gca knockout and anti-grancalcin antibody protected against skeletal deterioration in obesity and LPS-induced inflammation models.
- Obese humans (n=40) had higher serum grancalcin levels.
Methodological Strengths
- Convergent evidence across obese mice, fecal microbiota transfer, genetic knockout, and neutralizing antibody interventions
- Human validation of grancalcin elevation supporting translational relevance
Limitations
- Human sample size is modest and observational
- Fracture outcomes not assessed; bone endpoints primarily preclinical
Future Directions: Evaluate anti-grancalcin strategies and senolytics in larger animal models and early-phase human trials; assess biomarker utility of serum grancalcin for risk stratification.
Obesity is associated with skeletal deterioration and increased fracture risk, but the underlying mechanism is unclear. Herein, it is shown that obese gut microbiota promotes skeletal deterioration by inducing bone marrow macrophages (BMMs) senescence and grancalcin (GCA) secretion. Obese mice and those receiving obese fecal microbiota transplants exhibit increased senescent macrophages and elevated GCA expression in the bone marrow. In a study of 40 participants, it is found that obese patients are associated with higher serum GCA levels. It is further revealed that obese gut-microbiota derived lipopolysaccharides (LPS) stimulate GCA expression in senescent BMMs via activating Toll-like receptor 4 pathway. Mice with depletion of the Gca gene are resistant to the negative effects of obesity and LPS on bone. Moreover, neutralizing antibody against GCA mitigates skeletal deterioration in obese mice and LPS-induced chronic inflammation mouse model. The data suggest that the interaction between gut microbiota and the immune system contributes to obesity-associated skeletal deterioration, and targeting senescent macrophages and GCA shows potential of protecting skeletal health in obese population.
3. Marine n-3 polyunsaturated fatty acids slow sleep impairment progression by regulating central circadian rhythms in type 2 diabetes.
Among 27,549 adults with T2D, habitual fish oil use associated with better sleep, and in a randomized trial fish oil improved sleep parameters while upregulating core clock genes. Mechanistically, DHA/EPA restore hypothalamic clock gene oscillations via RORα targeting and promoting BMAL1 nuclear translocation.
Impact: Combines population-scale association, randomized intervention, and mechanistic evidence linking n-3 PUFAs to circadian reprogramming in T2D—offering a low-risk dietary strategy to improve sleep health.
Clinical Implications: Clinicians may consider recommending marine n-3 PUFAs to T2D patients with sleep complaints, alongside standard care, given signals of improved sleep and plausible mechanistic rationale.
Key Findings
- Habitual fish oil use associated with improved sleep in a T2D cohort of 27,549 individuals.
- Randomized controlled trial showed fish oil supplementation improved sleep parameters and upregulated Clock, Bmal1, and Per2.
- DHA/EPA restored disrupted clock gene oscillations in hypothalamic neurons via RORα, facilitating BMAL1 nuclear translocation.
Methodological Strengths
- Integration of large cohort analysis with randomized controlled trial
- Mechanistic validation in neuronal models pinpointing RORα–BMAL1 axis
Limitations
- RCT sample size and duration not detailed in abstract
- Sleep outcomes and adherence measures require fuller reporting for clinical translation
Future Directions: Confirm efficacy in larger, longer RCTs with objective sleep measures (actigraphy/polysomnography) and assess metabolic and quality-of-life co-benefits.
The role of marine n-3 polyunsaturated fatty acids (PUFAs) in promoting sleep has been proposed, yet their benefits for patients with type 2 diabetes (T2D) and the underlying molecular mechanisms remain poorly understood. In this study, we identify a significant association between habitual fish oil use and improved sleep quality in a cohort of 27,549 patients with T2D. A subsequent randomized controlled trial demonstrates that fish oil supplementation enhances sleep parameters in patients with T2D, accompanied by the upregulation of core circadian clock genes, including Clock, Bmal1, and Per2. In vitro, DHA and EPA restore the rhythmic oscillations of key clock genes in hypothalamic neurons disrupted by palmitic acid. Notably, n-3 PUFAs target RORα to regulate circadian clock oscillations and facilitate BMAL1 nuclear translocation. Collectively, our findings highlight the potential of marine n-3 PUFAs as a dietary intervention to improve sleep health in patients with T2D. This study was registered at ClinicalTrials.gov (NCT03708887).